Cancer Genetics (NASDAQ:CGIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cancer Genetics (NASDAQ:CGIX – Get Rating) in a report released on Monday. The brokerage set a “sell” rating on the stock.

Shares of NASDAQ:CGIX opened at $4.61 on Monday. Cancer Genetics has a 52-week low of $2.11 and a 52-week high of $17.50. The firm has a 50 day moving average price of $0.96.

About Cancer Genetics (Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Read More

• Get a free copy of the StockNews.com research report on Cancer Genetics (CGIX)
• MarketBeat: Week in Review 5/30 – 6/3
• Dividend Capture Strategy: What You Need to Know
• Xiaomi Co: Facing Macro Headwinds
• Okta On Verge Of Multi-Week Rally
• Don’t Bet On A Bounce For RH 

Want More Great Investing Ideas?